Loading ...

rat IgG2a monoclonal anti-human CD44 antibody-conjugated orthopyridyl-disulfide-poly(ethylene glycol)-functionalized thiol-terminated poly(ethylene glycol)-functionalized citrate-capped gold nanoparticles aqueous solution

Based on

1 Articles
2015 Most recent source

Composition

1

citrate-stabilized gold nanoparticles

citrate-stabilized Au nanoparticles citrate-capped gold nanoparticles citrate-coated gold nanoparticles citrate-capped Au nanoparticles citrate-stabilized gold NP citrate-stabilized Au NP citrate-stabilized AuNP citrate-capped gold NP citrate-stabilized GNP citrate-coated gold NP citrate-capped Au NP citrate-capped AuNP gold nanoparticles Au nanoparticles gold NP Au NP AuNP GNP
Type Nano Material
Formula
Role core
2

orthopyridyl-disulfide-poly(ethylene glycol)

OPSS-PEG
Type Polymer
Formula
Role layer
3

IgG2a monoclonal anti-human CD44 antibody

Type Biomolecule
Formula
Role layer
4

thiol-terminated poly(ethylene glycol)

HS-PEG
Type Polymer
Formula
Role layer

Properties

General physical and chemical properties

Property Value Nanomaterial Variant Source
colloidal stability

More information/entries available to subscribers only.

Or, view sample content

Applications

Area Application Nanomaterial Variant Source
medicine/veterinary

More information available to subscribers only.

Or, view sample content

Characterization

Method Nanomaterial Variant Source
UV-Vis-NIR optical spectroscopy

More information available to subscribers only.

Or, view sample content

Biological effects

Biological system Test details Nanomaterial Variant Source
human breast cancer MDA-MB-231 cells

More information/entries available to subscribers only.

Or, view sample content

Preparation

Method 1

Type: Physical formation
Source:
  1. q0cYb
  2. MSoBCmD
Product

rat IgG2a monoclonal anti-human CD44 antibody-conjugated orthopyridyl-disulfide-poly(ethylene glycol)-functionalized thiol-terminated poly(ethylene glycol)-functionalized citrate-capped gold nanoparticles aqueous solution

Size: not specified

Medium/Support: none

Method 2

Type: Chemical synthesis
Source:
Starting materials
  • IgG2a monoclonal anti-human CD44 antibody
  • orthopyridyl-disulfide-poly(ethylene glycol)-N-hydroxysuccinimide ester
  1. fve
  2. 85PGO74SaDkzrHSZW0iUhjDlkT9A
  3. RWBLB
  4. QG3TVY
  5. h4LIVJz
Product

rat IgG2a monoclonal anti-human CD44 antibody-conjugated orthopyridyl-disulfide-poly(ethylene glycol)-functionalized thiol-terminated poly(ethylene glycol)-functionalized citrate-capped gold nanoparticles aqueous solution

Size: not specified

Medium/Support: none

Method 3

Type: Chemical synthesis
Source:
Starting materials
  • IgG2a monoclonal anti-human CD44 antibody
  • orthopyridyl-disulfide-poly(ethylene glycol)-N-hydroxysuccinimide ester
  1. uSX
  2. yPGw6ij9CW0t7u01QS5tck5n7mZG
  3. qDhTr
  4. 53EKdV
  5. wglt7gc
Product

rat IgG2a monoclonal anti-human CD44 antibody-conjugated orthopyridyl-disulfide-poly(ethylene glycol)-functionalized thiol-terminated poly(ethylene glycol)-functionalized citrate-capped gold nanoparticles aqueous solution

Size: not specified

Medium: water

Support: none

Method 4

Type: Physical formation
Source:
  1. QQO6D
  2. Gvxu9mk
Product

rat IgG2a monoclonal anti-human CD44 antibody-conjugated orthopyridyl-disulfide-poly(ethylene glycol)-functionalized thiol-terminated poly(ethylene glycol)-functionalized citrate-capped gold nanoparticles aqueous solution

Size: not specified

Medium/Support: none

Method 5

Type: Chemical synthesis
Source:
Starting materials
  • IgG2a monoclonal anti-human CD44 antibody
  • orthopyridyl-disulfide-poly(ethylene glycol)-N-hydroxysuccinimide ester
  1. aHr
  2. h0aP9zuCKlrgi6G88j5WlNJdy7P6
  3. FFI3f
  4. nfQ904
  5. uCNWQrF
Product

rat IgG2a monoclonal anti-human CD44 antibody-conjugated orthopyridyl-disulfide-poly(ethylene glycol)-functionalized thiol-terminated poly(ethylene glycol)-functionalized citrate-capped gold nanoparticles aqueous solution

Size: not specified

Medium/Support: none

References

Full content is available to subscribers only

To view content please choose from the following:

We use cookies to improve your experience with our site. More information

Sign up for a free trial